Abstract
AbstractThe rapid biotechnological progress has promoted the development of novel medicinal therapies which are currently changing medical practice substantially. Patients may benefit from new opportunities for the treatment of various diseases, but on the other hand new risks have to be faced. To ensure timely access of patients to innovative medicines while taking safety aspects into consideration, an appropriate legislation is needed. This review aims at giving an overview of the role of the so called “Advanced Therapy Products” in today's medical practice and describes their current regulation in the European Union (EU).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
